This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
MagForce AG (Frankfurt, XETRA: MF6), the leading medical device company in the field of nanomedicine with focus on oncology, announced that Jan zur Hausen was unanimously elected to the company's Supervisory Board. Jan zur Hausen is a managing shareholder of Bergmann zur Hausen & Cie. GmbH, a corporate finance company that evolved from Sal. Oppenheim‘s investment banking activities.


http://www.magforce.de


MAPPER Lithography announced the signing of a deal for a financing round of EUR80 million. The round is led by RUSNANO (EUR40 m). Another EUR40 million will be contributed by current share- holders like ADP Industries, the investment vehicle of Mr. Arthur Del Prado, investment firm Parcom Capital (Parc-IT), Hoving & Partners along with Dutch high-end technology suppliers such as Technolution and DEMCON and innovation credits from AgentschapNL. Also other parties such as a number of Dutch individuals and family investment offices will contribute to the total amount. MAPPER MAPPER Lithography, founded out of Delft University of Technology, is a Delft-based company focusing on maskless e-beam direct-write lithography.


http://www.mapperlithography.com


MicroVision, Inc.(NASDAQ:MVIS), a leader in innovative ultra-miniature projection display technology, announced its operating and financial results for the second quarter of 2012 and the advan- cement of its 2012 business objectives. During the second quarter, MicroVision received purchase orders totaling $4.4 million from Pioneer Corporation in support of its Cyber Navi car navi- gation system, which began shipping in July 2012. MicroVision began deliveries in the second quarter and expects to increase volume and revenue in the second half of 2012. In July, the company received $1.4 million in additional purchase orders for PicoP Gen 2 components from Pioneer Corporation scheduled for delivery in 2013, bringing the total orders to $5.8 million. During the quarter the company raised $14.6 million net of issuance cost through equity offerings. The following financial results are for three and six months ended June 30, 2012, compared to the same periods one year earlier. Revenue was $1.3 million for the second quarter of 2012, compared to $1.2 million for the second quarter of 2011, and $3.0 million for the first half of 2012, compared to $2.3 million for the first half one year ago. Backlog was $5.4 million as of June 30, 2012. Net loss was $5.0 million, or $0.26 per share, for the quarter, compared to $9.2 million, or $0.69 per share, for the same quarter a year ago. Net loss was $14.8, or $0.82 per share, for the first half of 2012, compared to $18.2 million, or $1.39 per share, for the first half of 2011. As of June 30, 2012, cash and cash equivalents were $14.8 million.


http://www.microvision.com


 

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105